

## Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes

Nabil M. Abdel-Hamid,\* Maiiada H. Nazmy,\* Manal I. Abdel-Ghany,\*\* Walaa H. Nazmy\*\*\*

\* Biochemistry Department, Faculty of Pharmacy, Minia University, Egypt.

\*\* Pathology Department, Faculty of Medicine, Minia University, Egypt. \*\*\* Physiology Department, Faculty of Medicine, Minia University, Egypt.

### ABSTRACT

**Purpose.** To explore the possible intermediary pathways through which diabetes mellitus (DM) adversely worsens hepatocellular carcinoma (HCC), focusing on cell life controllers as some transcription factors and inflammatory mediators. **Material and methods.** Forty male albino rats were divided into four groups, control, cancer [given single intra-peritoneal (IP) dose of diethyl nitrosamine, NDEA, 125 mg/kg body weight], diabetic (given single dose of streptozotocin, STZ, 65 mg/kg) and cancer diabetic. HCC was initiated with NDEA, 3 weeks later, DM was induced with STZ. At 14th week, animals were sacrificed. Serum ALT, AST, GGT activities, AFP, IL-6, TNF- $\alpha$  levels and liver tissue Bax and Bcl2 proteins were measured. Liver sections were stained for histological examination. Both histological and AFP variations were chosen to prove cancer development. **Results.** NDEA group showed significant increase in liver weight, serum ALT, AST, GGT, AFP, TNF- $\alpha$ , IL-6 and liver Bcl2 protein with decrease in total body weight, liver Bax protein and Bax/Bcl2 ratio. These effects were more pronounced in DENA plus STZ group. IL-6, TNF- $\alpha$  and Bcl2 were positively correlated while Bax and Bax/Bcl2 ratio were negatively correlated to AFP levels reflecting potential diagnostic value. **Conclusion.** Co-induction of DM in the course of hepatocarcinogenesis can dramatically influence disease progression through inflammation and retarded apoptosis. The suggested apoptotic and inflammatory markers seem to be beneficial diagnostic tools for HCC and improve the diagnostic performance of AFP.

**Key words.** Alpha-fetoprotein. Apoptosis. Diabetes mellitus. Diethyl nitrosamine. Hepatocellular carcinoma. Inflammation.

### INTRODUCTION

Hepatocellular carcinoma (HCC) is the third deadliest and fifth most common malignancy worldwide.<sup>1-4</sup> It is a highly malignant tumor with high morbidity and mortality, showing poor prognosis due to its rapid infiltrating power and complicating liver cirrhosis.<sup>5,6</sup> Hepatocarcinogenesis is a multi-factor, multi-step and complex process, which is associated with a background of chronic and persistent infection of hepatitis B or C virus, alcohol consumption or aflatoxin B1 exposure.<sup>7-9</sup> HCCs are

phenotypically (morphology and microscopy) and genetically heterogeneous tumors, possibly reflecting in part the heterogeneity of etiologic factors implicated in HCC development, the complexity of hepatocyte functions and the late stage at which HCCs usually become clinically symptomatic and detectable.<sup>10,11</sup> Malignant transformation of hepatocytes may occur regardless the etiologic agent through a pathway of increased liver cell turnover, induced by chronic liver injury and regeneration in a context of inflammation, immune response, and oxidative DNA damage.<sup>12,13</sup> Generally, epidemiology of HCC is characterized by marked demographic and geographic variations.<sup>14</sup> It has been found that management of HCC is influenced not only by the tumor status and underlying liver function, but also by any other co-morbid illness. Diabetes is one of the most common co-morbid illnesses found in HCC patients that may directly influence the patient prognosis and survival.<sup>15,16</sup>

**Correspondence and reprint request:** Dr. Nabil Mohie Abdel-Hamid  
Diagnostic Laboratory, Abtal El-Faluga Street  
Mit-Gomre, Dakahlia, Egypt  
E-mail: nabilmohie@yahoo.com

*Manuscript received: July 09, 2011.  
Manuscript accepted: October 03, 2011.*

However, the pathophysiological mechanisms underlying this association is still not clear.<sup>17</sup> Apoptosis represents a physiological way to eliminate excess cells during both liver development and regeneration.<sup>18,19</sup> It is a highly preserved and controlled mechanism to achieve tissue homeostasis through targeted elimination of single cells without disrupting the biological functionality of the tissue. The morphological changes associated with apoptosis include nuclear condensation, cell shrinkage, and plasma membrane blobbing resulting in apoptotic bodies.<sup>20,21</sup>

Apoptotic signalling within the cell is transduced mainly via two molecular pathways; the death receptor pathway (the extrinsic pathway) and the mitochondrial pathway (the intrinsic pathway). Both of them activate a variety of proteases, mainly caspases (cysteiny aspartate-specific proteases), and endonucleases, which finally degrade cellular components.<sup>22</sup> The Bcl-2 family is the best characterized protein family involved in the regulation of apoptotic cell death. It includes both anti-apoptotic members (i.e. Bcl-2) and pro-apoptotic members (i.e. Bax), thus Bcl-2 family acts as a critical life-death decision point makers in the common pathway of apoptosis.<sup>23,24</sup> While acute inflammation is a part of the defence response, chronic inflammation can lead to certain diseases as cancer and diabetes.<sup>25,26</sup>

Epidemiological studies have shown that chronic inflammation predisposes to certain cancers. Most precancerous and cancerous tissues show signs of inflammation; this involves the movement of innate immune cells into the tissue, the presence of specific inflammatory signalling molecules (i.e. cytokines and chemokines) changes in tissue structure (remodelling), and the formation of new blood vessels (angiogenesis). Further studies found that cancer-associated inflammation actually promotes tumour growth and progression.<sup>27,28</sup> Several pro-inflammatory gene products (i.e. TNF- $\alpha$  and IL-6) play a critical role in apoptosis, proliferation, angiogenesis, invasion, and metastasis. Their expression is mainly regulated by the nuclear factor kappa-B (NF- $\kappa$ B), a transcription factor, which is constitutively active in most tumors and is induced by carcinogens and chemotherapeutic agents.<sup>29</sup>

This study aimed to investigate closely the possible intermediary mechanisms that might aggravate hepatocellular carcinogenesis after confounding by DM. We focused on cell life playmakers as apoptosis and inflammation mediators, to uncover the role of apoptosis and inflammation during experimental hepatocarcinogenesis through monitoring levels of

apoptotic regulators (i.e. Bcl2 and Bax) and inflammatory mediators (i.e. TNF- $\alpha$  and IL-6) and how they contribute to morbidifying co-existence of both HCC and DM. Liver histological and AFP changes were taken as markers for developing HCC.

## MATERIAL AND METHODS

### Animals

Forty male albino rats (3 months old) weighing from (145-180 g) were used in this study. They were divided in to equal 4 experimental groups (A-D) (10 rats per group), kept under constant environmental and nutritional conditions for two weeks then placed on a standard 26% casein diet with water ad libitum during the whole period of the experiment. Individual body weights were recorded weekly.

### Chemicals

Diethyl nitrosoamine (NDEA), streptozotocin (STZ) were purchased from Sigma Chemical Company, St Louis, MO, USA. All other chemicals and solvents used in the study were of analytical grade and were obtained from Sigma chemical company unless otherwise mentioned.

### Experimental design

- **Normal control.** Received saline only, by intraperitoneal (IP) route.
- **Diabetic control.** Acute diabetes was produced by a single IP injection of freshly prepared STZ solution, at a dose of 65 mg/kg body weight in 0.05% M citrate buffer, pH 4.5 and given within 10 min of dissolution. DM was ascertained by monitoring blood glucose levels using a standard Randox glucose kit. Blood glucose levels above 200 mg/dL.<sup>30</sup>
- **NDEA control.** Hepatic carcinogenesis was initiated by a single sub-necrogenic IP dose of DENA, 125 mg/kg body weight in 0.9% normal saline to initiate hepatocarcinogenesis.<sup>30</sup>
- **NDEA + STZ.** Rats received a single sub-necrogenic IP dose of DENA to initiate hepatocarcinogenesis, then at 3rd week, rats received a single IP dose of STZ to produce acute diabetes.

### Sample preparation

By the end of the experiment at 14th week, all rats were fasted overnight then killed by exposure to

increasing concentration of CO<sub>2</sub>. Blood samples were obtained by cardiac puncture, left to clot for 1 hour at 37 °C, then centrifuged at 10,000 rpm at 4 °C to separate serum samples and kept at -80 °C for further use. Liver samples were quickly removed, washed thoroughly in ice-cold phosphate buffer solution (PBS) and desiccated. Individual liver weights were accurately recorded. Liver was divided into two portions, one for histological examination,<sup>31</sup> the other was frozen in liquid nitrogen and kept at -80 °C for biochemical investigations.

### Preparation of hepatic cytosol

Approximately 100 mg of livers from each rat were pulverized separately using a pestle and mortar under liquid Nitrogen. The resulting finely ground material from each sample was re-suspended in 1 mL of ice-cold 50 mM Hepes buffer, pH 7.5, containing 150 mM NaCl and 1 mM dithiothreitol. This buffer was fortified with complete EDTA-free protease inhibitor cocktail tablets at a dose of one tablet/10 mL buffer, as recommended by Roche diagnostics Ltd. (Lewes, East Sussex, U.K.). The pulverized hepatic material was placed on ice and homogenized mechanically by three separate 30 second pulses using an Omni homogenizer. The resulting extracts were subjected to two centrifugation steps at 4 °C (15,000 g for 45 min, followed by 100,000 g for 90 min). The final 100,000 g supernatants (cytosols) were collected and retained for biochemical analyses.<sup>32</sup>

### Biochemical analysis

Blood glucose levels and serum ALT, AST, GGT activities were measured using Randox kits on a Daytona auto analyzer.

### ELISA determination

High sensitivity kits were used for determinations. TNF- $\alpha$  was determined using rat ELISA kit from ABCAM, UK and IL-6 was determined using Endogen® rat ELISA kit from Pierce Biotechnology following the instructions of the manufacture. AFP determination,<sup>33</sup> using rat AFP kit from USCN life company/China, following the instructions of the manufacturer.

### Western blotting

After determination of individual protein content of in liver samples,<sup>34</sup> samples were prepared for

loading, amounts of loading buffer and distilled water were calculated depending on the protein concentrations of samples to produce 2 mg/mL sample stock, then the mixture was left in a boiling water bath for 5 min. Bcl2, Bax and GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) primary antibodies and secondary antibodies were obtained from Santa Cruz Technology, Inc, UK. GAPDH was used as a loading control to ensure equal loading and even transfer from the gel to the membrane across the whole gel. Electrophoresis and electroblotting were carried out in a Bio-Rad Mini-Protein II Cell apparatus (Bio-Rad Laboratories, Hemel Hempstead, UK) using a discontinuous buffer system. Aliquots of hepatic samples were routinely examined by SDS-PAGE and stained with Coomassie R250 immediately before immunoblotting to ensure equal loading of samples. Cross-reacting bands were visualized by enhanced chemiluminescence and resulting images were analyzed densitometrically.

### Statistical analysis

Data were expressed as mean  $\pm$  SD (n = 10 rats). Significant difference between groups was analysed by using GraphPad Prism 5 statistical software.

## RESULTS

### Biochemical investigations

Our initial observations were related to the general condition of the animals throughout the experiment. Initial body weights were comparable in all groups and ranged between (145-180 g), while final body weights differed significantly among groups. Cancer and/or diabetic groups showed significant decrease (p < 0.05) in their final body weights as compared to normal control combined with significant increase in relative liver weight (absolute liver weight/total body weight) (p < 0.05) compared to normal control (Table 1).

Groups treated with NDEA and or STZ showed significant increase in ALT, AST and GGT activities (P < 0.001) when compared to their corresponding controls, while diabetic groups showed non significant change in ALT activities but significant increase in AST and GGT activities (P < 0.01 and 0.001 respectively) compared to normal control. All STZ treated groups showed significant increase in blood glucose levels (P < 0.001), while NDEA control showed significant hypoglycemia (P < 0.01) as compared to normal control (Table 2).

**Table 1.** Initial and final body weight, absolute and relative liver weight for all groups.


Group	Initial body weight	Final body weight	Absolute liver weight	Relative liver weight
A Normal control	164.86 ± 8.95	254.63 ± 8.19	5.69 ± 0.402	0.022 ± 0.0018
B Diabetic control	168.75 ± 8.55	234.7 ± 7.25***	6.08 ± 0.44**	0.026 ± 0.0025*
C NDEA control	160.75 ± 11.35	213.7 ± 11.4***	10.41 ± 1.42***	0.049 ± 0.0041***
D NDEA + STZ	165.75 ± 8.18	213 ± 15.21 <sup>ns</sup>	11.03 ± 1.017 <sup>§</sup>	0.052 ± 0.0038 <sup>§</sup>

Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: \*\*\* P < 0.001 compared to normal control, § P < 0.001 compared to NDEA control. ns: non significant.

**Table 2.** Serum ALT, AST, GGT activities and blood glucose levels for all groups.

Group	ALT	AST	GGT	Glucose
A Normal control	41.5 ± 3.49	86.7 ± 7.85	19.52 ± 1.91	84.17 ± 7.31
B Diabetic control	48.28 ± 4.2*	102.5 ± 10.09 <sup>†</sup>	41.83 ± 3.79 <sup>‡</sup>	351.9 ± 26.08 <sup>‡</sup>
C NDEA control	129 ± 10.59 <sup>‡</sup>	234.4 ± 17.8 <sup>‡</sup>	80.87 ± 7.34 <sup>‡</sup>	69.15 ± 5.74 <sup>†</sup>
D NDEA + STZ	156.03 ± 13.54 <sup>§</sup>	249.4 ± 19.97 <sup>§</sup>	115.5 ± 10.1 <sup>§</sup>	314.73 ± 24.04 <sup>§</sup>


Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: ‡ P < 0.001, † P < 0.01, \* P < 0.05 compared to normal control, § P < 0.001 compared to NDEA control. ns: non significant.



**Figure 1.** Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 compared to normal control, \*\* P < 0.001 compared to NDEA control. ns: non significant.


Serum levels of AFP were significantly increased in DENA treated groups (P < 0.001) compared to normal control. This effect was more pronounced in NDEA + STZ treated groups, while diabetic control showed no significant change in AFP levels (Figure 1).

Serum levels of TNF- $\alpha$  and IL-6 were significantly increased in groups treated with NDEA alone or combined with STZ (P < 0.001) compared to controls. Diabetic control also showed significant increase (P < 0.001) compared to normal control (Figures 2 and 3).




**Figure 2.** Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 compared to normal control, \*\* P < 0.001 compared to NDEA control.

Western blotting for anti-apoptotic Bcl2 and pro-apoptotic Bax proteins in the liver of groups treated with NDEA with or without STZ demonstrated significant increase in expression of Bcl2 (P < 0.001). The same effect was also observed in NDEA + STZ treated group, compared to NDEA control, while diabetic control showed significant decrease in Bcl2 expression in the liver (P < 0.001) compared to normal control. On the contrary, Bax showed significant decrease in groups treated with NDEA alone or combined with STZ (P < 0.001) compared to their




**Figure 3.** Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 compared to normal control, \*\* P < 0.001 compared to NDEA control.




**Figure 4.** Data are expressed as  $\bar{X} \pm SD$  of three separate experiments. Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 compared to normal control, \*\* P < 0.05 compared to NDEA control.

corresponding controls, while diabetic control showed significant increase (P < 0.001) when compared to normal control (Figures 4 and 5).

Bax/Bcl2 ratio was significantly decreased in groups treated with NDEA with or without STZ (P < 0.001) compared to their corresponding controls.



**Figure 5.** Data are expressed as  $\bar{X} \pm SD$  of three separate experiments. Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 and \*\* P < 0.01 compared to normal control, \*\*\* P < 0.01 compared to NDEA control.



**Figure 6.** Data are expressed as  $\bar{X} \pm SD$  of 10 rats in each group (n = 10). Significant difference between groups is analyzed by one-way ANOVA test, where: \* P < 0.001 compared to normal control, \*\* P < 0.01 compared to NDEA control.

On the other hand, diabetic control showed significant increase in Bax/Bcl2 ratio (P < 0.001) compared to normal control (Figure 6).

Comparative correlation coefficients for all parameters to AFP levels depicted that, TNF- $\alpha$ , IL-6 and Bcl2 were positively correlated (r = 0.9738,




Figure 7. Correlation between AFP vs. different parameters.

0.9647, 0.9305 respectively) ( $P < 0.05$ ) while Bax and Bax/Bcl2 ratio were negatively correlated to AFP ( $r = -0.8897, -0.8632$  respectively) ( $P < 0.05$ ) (Figure 7).

### Histological examinations

Normal control had normal hepatic lobular architecture and normal hepatocytes with granulated cytoplasm and small uniform nuclei (Figure 8A). On the other hand, diabetic control showed massive fat accumulation and inflammatory infiltration in the form of mononuclear inflammatory cells (Figure 8B). Groups treated with NDEA and/or STZ showed hydropic degeneration or cloudy swelling, focal areas of necrosis, portal inflammation in the form of infiltration with mononuclear inflammatory cells, bile stasis and proliferation of bile ducts. Hepatocytes showed partial loss of architecture, a tendency to spread by intrahepatic veins, significant hepatic and portal tumor thrombi. Tumor cells are growing in nests and thick cords that are separated from one another by thin walled sinusoids. Cytologically the tumor cells bear some resemblance to normal hepatocytes but they are slightly larger, have more irregular and prominent hyperchromatic nuclei (Figure 8C and 8D). These manifestations were more pronounced in groups treated with NDEA + STZ if compared to groups treated with NDEA alone (Figure 8E and 8F).


### DISCUSSION

HCC and DM have repeatedly been shown to occur together about twice as frequently as would be expected if being alone.<sup>1,9,35,36</sup> Because of this frequent association, studying the impact of DM on

the incidence and management of HCC is of considerable clinical interest.<sup>17,37,38</sup> In this study, animals treated with NDEA alone showed definite histological, elevated AFP levels in serum, as well as, molecular changes which reflected severe hepatocellular damage and poor hepatic function. AFP is always used to assess and follow up HCC diagnostically and prognostically, although some additional markers were recommended to elevate its clinical utility.<sup>39</sup>

NDEA can cause necrotic damage and force the initiated hepatocytes to enter cell cycle, then when appropriate promoter is applied, hepatocytes undergo clonal expansion and proliferation.<sup>40</sup> NDEA undergoes metabolic activation by cytochrome P450 enzymes forming reactive electrophiles which are cytotoxic, mutagenic and carcinogenic. It is transported through blood, induce hepatic damage with subsequent release of hepato-specific enzymes (transaminases) into circulation.<sup>41</sup> GGT may be elevated as a response to oxidative stress accumulated during cancer progression, facilitating increased transport of GSH precursors into cells or alternatively as a result of normal cell turnover and cellular stresses possibly through increases in proteolysis, glycosylation, increased GGT synthesis and endothelial cell damage.<sup>42-44</sup> Our observations also showed significant induction of Bcl2 expression joined with significant decrease in Bax expression in liver of rats bearing HCC, additionally significant decrease in the overall Bax/Bcl2 ratio in tumor tissues. These data give clue for disrupted apoptotic signals in tumor tissue in favour of anti-apoptotic Bcl2 over the pro-apoptotic Bax (carcinogenesis). This is thought to be a defence mechanism by which tumor cells can survive.<sup>23</sup> A significant number of the molecular events described to be altered in HCC progression are compromising the balance between survival and apoptotic signals in the preneoplastic hepatocytes.<sup>45</sup> Many cancer cells, through the up-regulation of Bcl2 gene, resist apoptosis, allowing damaged and mutated cells to survive, and ultimately proliferate. It also prolongs the lifespan of cells, and makes them more likely to develop mutations.<sup>46</sup>

Our findings also revealed that levels of TNF- $\alpha$  and IL-6 were significantly increased in rats bearing hepatoma which reflects an aggressive inflammatory response correlated with tumor induction. It is believed that inflammation acts as a key regulator in promotion of initiated hepatocytes, possibly by providing them with proliferating signals and by preventing apoptosis.<sup>47</sup> Inflammatory responses produce cytokines, which may act as growth and/or angiogenic factors insulting transformed cells to



**Figure 8.** Representative photomicrographs of liver sections from different groups. **A.** Normal control: showed normal hepatic lobular architecture and normal hepatocytes with granulated cytoplasm and small uniform nuclei. **B.** Diabetic (STZ) control showed massive fat accumulation and inflammatory infiltration in the form of mononuclear inflammatory cells. **C, D.** Animals treated with NDEA only. **E, F.** Animals treated with NDEA+STZ. These sections showed hydropic degeneration or cloudy swelling, focal areas of necrosis, bile stasis and portal inflammation. Tumor cells showed loss of architecture, growing in nests and thick cords that are separated from one another by thin walled sinusoids. Cytologically the tumor cells bear some resemblance to normal hepatocytes but they are slightly larger, have more irregular and prominent hyperchromatic nuclei, These effects were more pronounced in groups treated with both NDEA + STZ if compared to groups treated with NDEA only (hematoxylin and eosin, X = 200, for all photomicrographs).

proliferate and undergo promotion.<sup>48</sup> Moreover, tumor-infiltrating lymphocytes secrete matrix-degrading proteinases, thereby promoting neoplastic proliferation, angiogenesis, and invasion.<sup>49,50</sup> These inflammatory mediators may contribute to HCC progression through a number of mechanisms.<sup>27</sup> It is believed that during liver inflammation, hepatocytes are exposed to increased levels of these cytokines, as well as oxidative stress and bile acids.<sup>26</sup> Depending on the context and exposure of hepatocytes to TNF- $\alpha$ , it can induce signals that mediate cell death, or alternatively, survival pathways that allow hepatocytes to tolerate tissue damage, so insufficient hepatocyte apoptosis associated with failure to remove mutated cells or with unrestrained proliferation can promote development of liver cancer.<sup>25</sup> Hepatic carcinogenesis can also arise from sustained hepatocyte cell death due to the high rate of compensatory regeneration invoked in the tissue, thus elevating the risk of mitotic errors.<sup>51</sup> NF- $\kappa$ B is the master regulator of inflammation, it is a natural suspect in providing a mechanistic link between inflammation and apoptosis during carcinogenesis.<sup>52-54</sup>

Inhibition of apoptosis is perhaps the most obvious way through which NF- $\kappa$ B signals hepatocarcinogenesis as many NF- $\kappa$ B target genes prevent apoptosis (i.e. Bcl2).<sup>54,55</sup> During late tumorigenesis, NF- $\kappa$ B activation protects the tumor cells against cell death. Moreover, the tumor cells are provided with essential growth factors due to NF- $\kappa$ B activation in non-parenchymal cells of the liver, such as Kupffer cells.<sup>56,57</sup>

When diabetes is introduced into the equation most of the observed histological and biochemical abnormalities were amplified. This may be attributed to diabetes related hyperglycaemia which may predispose the liver to relative insulin resistance. The excess free fatty acids found in the insulin-resistant state is directly toxic to hepatocytes via cell membrane disruption, mitochondrial dysfunction, toxin formation and activation or inhibition of key steps in the regulation of metabolism. Other potential explanations include oxidant stress from reactive lipid peroxidation, peroxisomal beta-oxidation, and recruited inflammatory cells.<sup>58</sup> In this study, groups treated with both NDEA and STZ showed higher levels of transaminases which may be attributed to impaired insulin signalling rather than pure hepatocyte injury.<sup>59</sup> In addition, higher GGT activities may be a compensatory mechanism for the preservation of glutathione stores, thus increased GGT activities may be a response to oxidative stress caused by the diabetic state.<sup>60</sup> These groups also showed higher le-

vels of circulatory TNF- $\alpha$  and IL-6 and more pronounced inhibition of apoptosis. It is believed that metabolic disturbances associated with diabetes can lead to activation of the polyol pathway, high levels of the cytokines, formation of advanced glycation end-products (AGEs), activation of protein kinase C and enhanced oxidative stress.<sup>61,62</sup> The activation of these pathways may be especially important in initiating events linked to inflammation and apoptosis.<sup>63-65</sup>

## CONCLUSIONS

The co-existence of diabetes in the course of hepatocarcinogenesis can dramatically worsen disease status. In this study, diabetes acted as a promoter for HCC, it negatively affected the general condition of the rats, prognosis and outcome of the resultant hepatoma. A possible interplay between inflammation and apoptosis may be involved in mediating this promoting effect in this model of NDEA-initiated, STZ-promoted hepatocarcinogenesis. Suggested apoptotic and inflammatory markers (TNF- $\alpha$ , IL-6, Bcl2 and Bax) seem to be beneficial diagnostic tools that may help to improve performance of AFP since they are well correlated with AFP levels.

## CONFLICT OF INTEREST STATEMENT

There are no conflicts of interest.

## ACKNOWLEDGEMENT

The histological part of the study was executed and interpreted by Prof Manal Ismail Abdel-Ghany, Ph.D., Pathology Department, College of Medicine, Minia University, Egypt. Grateful acknowledgement and appreciation to Dr. Salama Mohammed Rabie, lecturer of Biochemistry, Faculty of Medicine, Minia University for his kind cooperation in biochemical examination.

## REFERENCES

1. El-Serag HB. Epidemiology of hepatocellular carcinoma. *Clin Liver Dis* 2001; 5: 87-107, vi.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. *J Clin Gastroenterol* 2002; 35: S72-S78.
3. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. *Asian Pac J Cancer Prev* 2004; 5: 118-25.
4. Blum HE. Hepatocellular carcinoma: therapy and prevention. *World J Gastroenterol* 2005; 11: 7391-400.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; 37: 429-42.

6. Abdel-Hamid NM. Recent insights on risk factors of Hepatocellular carcinoma. *World J Hepatol* 2009a; 15: 3-7.
7. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. *World J Gastroenterol* 2001; 7: 445-54.
8. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. *Rev Gastroenterol Disord* 2003; 3: 8-24.
9. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. *Hepatology* 2002; 36: 1206-13.
10. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. *Oncogene* 2003; 22: 5093-107.
11. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. *Semin Liver Dis* 2004; 24: 77-88.
12. Brecht C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 2004; 127: S56-S61.
13. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology* 2004; 127: S72-S78.
14. el-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J Gastroenterol* 2005; 11: 5193-8.
15. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. *Dig Dis Sci* 2002; 47: 710-5.
16. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. *J Clin Gastroenterol* 2002; 35: 266-9.
17. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; 54: 533-9.
18. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. *World J Gastroenterol* 2009; 15: 513-20.
19. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *British J Cancer* 1972; 26: 239-57.
20. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* 2003; 3: 745-56.
21. Shi-Yong S. Apoptosis as a novel target for cancer chemoprevention. *J National Cancer Institute* 2004; 96: 662-72.
22. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. *Gut* 2005; 54: 1024-33.
23. Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. *Liver Int* 2006; 26: 904-11.
24. Zhao Y, Li S, Childs EE, Kuharsky DK, Yin XM. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. *J Biol Chem* 2001; 276: 27432-40.
25. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature* 2004; 431: 405-6.
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; 357: 539-45.
27. Balkwill F. Tumor necrosis factor or tumor promoting factor? *Cytokine Growth Factor Rev* 2002; 13: 135-41.
28. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell* 2005; 7: 211-7.
29. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? *Biochem Pharmacol* 2006; 72: 1605-21.
30. Saha BK, Sarkar A, Basak R, Chatterjee M. 1alpha, 25-Dihydroxyvitamin D3 suppresses the effect of streptozotocin-induced diabetes during chemical rat liver carcinogenesis. *Cell Biol Int* 2001; 25: 227-37.
31. Van Gieson I. Van Gieson stain. In: Theory and practice of histological techniques. Churchill Livingstone Edinburgh; 1982.
32. Chanas SA, Jiang Q, McMahon M, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. *Biochem J* 2002; 365: 405-16.
33. Sell S, Becker FF. alpha-Fetoprotein. *J Natl Cancer Inst* 1978; 60: 19-26.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72: 248-54.
35. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. *J Natl Cancer Inst* 2000; 92: 1096-9.
36. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. *Cancer* 2004; 101: 1009-17.
37. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. *Hepatology* 2006; 43: 1295-302.
38. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. *Int J Cancer* 2006; 118: 2105-9.
39. Awadallah A, Issa HA and Soliman, MS. Evaluation of Serum Chromogranin A as a Useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma. *J Am Sci* 2011; 7: 999-1007.
40. Bhattacharya N. A new experimental model of rat hepatocellular carcinoma. *Exp Oncol* 2003; 25: 55-9.
41. Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. *Mol Cell Biochem* 2008; 319: 51-9.
42. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. *Cancer* 2000; 88: 761-9.
43. Joyce-Brady M, Jean JC, Hughey RP. gamma -glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response. *J Biol Chem* 2001; 276: 9468-77.
44. Yao DF, Dong ZZ, Yao DB, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. *Hepatobiliary Pancreat Dis Int* 2004; 3: 564-70.
45. Volkman M, Schiff JH, Hajjar Y, et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. *J Mol Med* 2001; 79: 594-600.
46. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. *Oncogene* 2006; 25: 3848-56.
47. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. *J Clin Invest* 2005; 115: 2625-32.
48. Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? *Breast Dis* 2004; 20: 145-53.

49. Abdel-Hamid NM. Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats. *J Membr Biol* 2009b; 230: 155-62.
50. Mantovani A. Cancer: inflammation by remote control. *Nature* 2005; 435: 752-3.
51. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol* 2005; 5: 749-59.
52. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; 100: 57-70.
53. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* 2002; 2: 301-10.
54. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006; 441: 431-6.
55. Tapia MA, Gonzalez-Navarrete I, Dalmases A, et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. *Cell Cycle* 2007; 6: 2284-92.
56. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. *Endocr Rev* 2007; 28: 365-86.
57. Singh S, Shi Q, Bailey ST, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. *Mol Cancer Ther* 2007; 6: 1973-82.
58. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 2003; 37: 1202-19.
59. O'Brien RM, Granner DK. Regulation of gene expression by insulin. *Biochem J* 1991; 278(Pt. 3): 609-19.
60. Brown-Borg HM, Rakoczy SG. Glutathione metabolism in long-living Ames dwarf mice. *Exp Gerontol* 2005; 40: 115-20.
61. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. *Diabetes* 2003; 52: 506-11.
62. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis—impact on periodontal pathology. *J Dent Res* 2006; 85: 15-21.
63. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. *Br J Pharmacol* 2000; 130: 963-74.
64. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. *Diabetes* 2004; 53: 2404-11.
65. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. *Curr Eye Res* 2004; 28: 251-6.